Primary Job Title Founder, President, CEO and Chairman of the Board Primary Organization 
Naia Pharmaceuticals
Location Greenbrae, California, United States Regions San Francisco Bay Area, West Coast, Western US Gender Male
LinkedIn View on LinkedIn
H. Daniel Perez, MD, a Venture Partner with Bay City Capital since 2007, was previously President and CEO of Berlex (the US arm of Schering AG) where he led the company's R&D efforts in the US and overseas, initiated multiple human clinical trials, and oversaw the execution of numerous collaborations, licensing deals, spin-outs and
acquisitions, until leaving the company in 2006 upon its acquisition by Bayer. Dr. Perez is on the Board of Directors of Celtaxys and Presidio Pharmaceuticals, and serves on the Scientific Advisory Boards of Cardium and Vertex Pharmaceuticals. He is also a member of the Investment Board of GSK, China, and the President's Council for the Gladstone Institutes at the University of California, San Francisco (UCSF). He was a member of the Board of Directors of BayBio and Cleveland Biolabs. Dr. Perez received his medical degree in Buenos Aires, Argentina and completed his medical training at Beth Israel-Mount Sinai in New York City, as well as a fellowship in rheumatology and immunology at NYU. He joined the faculty at NYU as an Assistant Professor of Medicine and was a Professor of Medicine at UCSF until 1993. Dr. Perez has published extensively, has been elected to multiple scientific societies and nominated to the National Academy of Sciences.
